Bright Minds Biosciences Inc

Bright Minds Biosciences Inc. is a biotechnology company that develops therapeutics for patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 receptor serotonin agonists for epilepsy and neuropsychiatric disorders, and BMB-101, which has completed a phase 1 trial for an undisclosed seizure disorder and is in phase 2 trials for developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for neuropsychiatric and neurology indications, and BMB-105, a 5-HT2C agonist for Prader-Willi syndrome. It collaborates with Firefly Neuroscience, Inc. on analysis of electroencephalogram (EEG) data in its BREAKTHROUGH study, and was founded in 2017 with headquarters in New York, New York.